Somatic mutation landscapes at single-molecule resolution. by Abascal, Federico et al.
Somatic mutation landscapes at single-molecule resolution 1 
 2 
Federico Abascal1, Luke M. R. Harvey1,#, Emily Mitchell1,2,#, Andrew R. J. Lawson1,#, 3 
Stefanie V. Lensing1,#, Peter Ellis1,3,#, Andrew J. C. Russell1, Raul E. Alcantara1, Adrian 4 
Baez-Ortega1, Yichen Wang1, Eugene Jing Kwa1, Henry Lee-Six1, Alex Cagan1, Tim H. H. 5 
Coorens1, Michael Spencer Chapman1, Sigurgeir Olafsson1, Steven Leonard1, David Jones1, 6 
Heather E. Machado1, Megan Davies2, Nina F. Øbro2,4, Krishnaa T. Mahubani4,5,6, Kieren 7 
Allinson7, Moritz Gerstung8, Kourosh Saeb-Parsy5,6, David G. Kent2,9, Elisa Laurenti2,4, 8 
Michael R. Stratton1, Raheleh Rahbari1, Peter J. Campbell1,4, Robert J. Osborne1,10,*, Iñigo 9 
Martincorena1,*. 10 
 11 
# These authors contributed equally 12 
* Corresponding authors: r.osborne@biofidelity.com (R.J.O.), im3@sanger.ac.uk (I.M.) 13 
 14 
Affiliations: 15 
1 Wellcome Sanger Institute, Hinxton CB10 1SA, UK. 16 
2 Wellcome - MRC Cambridge Stem Cell Institute, Cambridge Biomedical Campus, 17 
Cambridge CB2 0AW, UK. 18 
3 Current address: Inivata, Glenn Berge Building, Babraham Research Campus, Babraham, 19 
Cambridge, CB22 3FH, UK 20 
4 Department of Haematology, University of Cambridge, Cambridge CB2 2XY, UK. 21 
5 Department of Surgery, University of Cambridge, Cambridge CB2 0QQ, UK. 22 
6 NIHR Cambridge Biomedical Research Centre, Cambridge Biomedical Campus, 23 
Cambridge CB2 0QQ, UK. 24 
7 Cambridge Brain Bank, Division of the Human Research Tissue Bank, Box 235, Level 5, 25 
Addenbrooke’s Hospital, Hills Rd, Cambridge, CB2 0QQ, UK. 26 
8 European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), 27 
Hinxton CB10 1SD, UK. 28 
9 York Biomedical Research Institute, Department of Biology, University of York, York 29 
YO10 5DD, UK. 30 
10 Current address: Biofidelity, 330 Cambridge Science Park, Milton Road, Cambridge, CB4 31 
0WN, UK 32 
 33 
 34 
Somatic mutations drive cancer development and may contribute to ageing and other 35 
diseases1,2. Yet, the difficulty of detecting mutations present only in single cells or small 36 
clones has limited our knowledge of somatic mutagenesis to a minority of tissues. To 37 
overcome these limitations, we introduce nanorate sequencing (NanoSeq), a new duplex 38 
sequencing protocol with error rates <5 errors per billion base pairs in single DNA 39 
molecules from cell populations. This rate is two orders of magnitude lower than typical 40 
somatic mutation loads, enabling the study of somatic mutations in any tissue 41 
independently of clonality. We exploited this single-molecule sensitivity to study somatic 42 
mutations in non-dividing cells across several tissues, comparing stem cells to 43 
differentiated cells and studying mutagenesis in the absence of cell division. 44 
Differentiated cells in blood and colon displayed remarkably similar mutation loads and 45 
signatures to their corresponding stem cells, despite mature blood cells having 46 
undergone considerably more divisions. We then characterised the mutational 47 
landscape of post-mitotic neurons and polyclonal smooth muscle, confirming that 48 
neurons accumulate somatic mutations at a constant rate throughout life without cell 49 
division, with similar rates to mitotically-active tissues. Altogether, our results suggest 50 
that mutational processes independent of cell division are important contributors to 51 
somatic mutagenesis. We anticipate that the ability to reliably detect mutations in single 52 
DNA molecules could transform our understanding of somatic mutagenesis and enable 53 




Somatic mutations occur in our cells as we age. Because most somatic mutations are present 58 
in small groups of cells or even in single cells, studying somatic mutagenesis has been 59 
challenging, requiring special approaches. This includes ultra-deep sequencing of small 60 
biopsies3-5, laser microdissection6-8, isolation of single-cells followed by in vitro expansion 61 
into organoids or colonies9-11, and single-cell sequencing12-14. While these technologies are 62 
changing our understanding of somatic mutagenesis, the error rates of single-cell approaches 63 
have, until recently15, been too high16, and other approaches are limited to mitotically-active 64 
cell types. 65 
 66 
As a result of these technical limitations, the rates and patterns of somatic mutation across 67 
most human cell types remain underexplored. This is especially the case for non-dividing 68 
cells, including differentiated cells that make the bulk of mitotically-active tissues and are 69 
responsible for tissue function, and post-mitotic tissues, such as cortical neurons or cardiac 70 
muscle, which are of particular interest in human ageing, neurodegeneration and 71 
cardiovascular disease. Post-mitotic tissues can also inform on the contribution of cell 72 
division and DNA replication to somatic mutation in human tissues. To address these 73 
questions, here we present a new sequencing protocol that enables the study of somatic 74 
mutations in any tissue or cell population by reliably detecting somatic mutations in single 75 
DNA molecules. 76 
 77 
Nanorate sequencing 78 
 79 
Several protocols have been developed to increase the accuracy of standard sequencing by 80 
barcoding individual molecules of DNA and sequencing each molecule multiple times, 81 
reducing error rates by single-molecule consensus17. The most accurate approaches use 82 
duplex consensus sequencing18,19, sequencing copies of both strands of a DNA molecule to 83 
remove sequencing errors (present in individual reads) and PCR errors (present in copies of 84 
one of the two strands) (Fig. 1a). Duplex sequencing has a theoretical error rate <10-9 85 
errors/bp, the probability of two early and complementary PCR errors in both strands17. 86 
Given that this rate is lower than the typical mutational load of human tissues, it raises the 87 
possibility of quantifying somatic mutation rates in genetically-heterogeneous samples, by 88 
detecting somatic mutations on single DNA molecules. This is the rationale of BotSeqS, a 89 
whole-genome duplex sequencing protocol20 (Fig. 1a). In practice, however, mapping errors 90 
and some library preparation artefacts can violate the assumed independence of both 91 
strands20,21. The actual error rates of duplex sequencing protocols have remained difficult to 92 
measure due to the lack of control samples with low and known mutation rates17. 93 
 94 
To evaluate the performance of BotSeqS, we used samples of cord blood, comparing 95 
BotSeqS on bulk granulocytes from a neonate to standard sequencing of 100 single-cell-96 
derived colonies from two neonates as a control. On average, single-cell-derived colonies had 97 
66 mutations per cell, dominated by C>T mutations at CpG sites. In contrast, BotSeqS 98 
estimated 1,240 mutations per diploid genome, dominated by C>A and C>G (Fig. 1b, c). 99 
Analysing the distribution of substitutions across BotSeqS reads revealed a large excess of 100 
G>T/C and C>T substitutions near the 5' ends of DNA fragments, and an imbalance over the 101 
complementary C>A/G and G>A substitutions affecting the entire read length (Fig. 1d, 102 
Extended Data Figs. 1 and 2). These imbalances are incompatible with real mutations and 103 
reflect errors introduced during library preparation22 (Methods, Supplementary Note 1). We 104 
found the same imbalances, with a much larger C>T component, in the original BotSeqS 105 
publication20 (Fig. 1d). Extensive trimming of read ends only partially alleviated these errors 106 
(Extended Data Fig. 2). Overall, we estimate that BotSeqS introduced approximately 1,200 107 
errors per diploid genome in our samples (i.e. ~2 x 10-7 errors/bp). 108 
 109 
Based on the error patterns, we reasoned that end repair was likely responsible for most 110 
errors, by converting DNA damage in single-strands of DNA into double-stranded errors 111 
(Fig. 1e and Extended Data Fig. 1c, d). To solve this, we developed NanoSeq, a protocol 112 
that prevents copying errors between strands by avoiding end repair and by blocking nick 113 
extension. First, we replaced sonication and end repair with restriction enzyme fragmentation 114 
(Fig. 1e, Methods, Supplementary Table 3, Supplementary Note 2). Although restriction 115 
enzymes provide partial coverage of the genome (29% using HpyCH4V), the fraction 116 
covered is sufficiently random to accurately estimate mutation rates and signatures. They also 117 
enable the generation of NanoSeq libraries from as little as 1 ng of DNA (Methods). 118 
Alternatively, we show that sonication followed by exonuclease blunting can be used for 119 
applications requiring whole-genome coverage (Methods, Supplementary Note 3, 120 
Extended Data Fig. 3). Second, we introduced non-A dideoxynucleotides (ddBTPs) during 121 
A-tailing, to avoid errors from nick extension (Fig. 1e, Methods, Extended Data Fig. 1e, 122 
Supplementary Note 4). Adapters with sufficiently diverse random barcodes were used to 123 
create single-molecule-derived read families (Supplementary Note 5). 124 
 125 
If duplicate rates are not optimised, duplex sequencing approaches can suffer from low 126 
efficiency due to suboptimal read family sizes20. We use mathematical modelling of family 127 
sizes and qPCR quantification of the library to maximise the duplex coverage independently 128 
of the amount of input DNA (Methods, Extended Data Fig. 4a-d). A robust bioinformatic 129 
pipeline was also developed to avoid false positive mutation calls from mapping errors and 130 
from low-level DNA contamination (Extended Data Fig. 4e, f, Methods, Supplementary 131 
Note 6), and to distinguish germline from somatic mutations.  132 
 133 
Applying NanoSeq to cord blood granulocytes yielded an estimated mutation rate of 109 134 
mutations per cell (95% Poisson confidence intervals 95-125; Fig. 1g). The small difference 135 
with the colonies could be due to NanoSeq errors, a higher mutation burden in granulocytes 136 
than in cord blood stem cells, or both. Consistent with most mutations detected by NanoSeq 137 
being genuine, no substitution imbalances were detected in the NanoSeq calls (Fig. 1d) and 138 
no significant differences were found between the mutational spectra of colonies and 139 
granulocytes (Fig. 1c, Methods). As an additional low-burden control, we applied NanoSeq 140 
to a sperm sample from a 21-year-old donor. Seven NanoSeq replicates of the sperm sample 141 
yielded low mutation burdens, with ~52 mutations per haploid sperm cell (1.8 x 10-8 142 
mutations/bp or ~2.5 mutations/year/cell), consistent with current estimates of the mutation 143 
rate in the paternal germline from trio studies23,24 (Fig. 1f). Together, the sperm and cord 144 
blood data indicate that the error rate of NanoSeq is lower than 5 x 10-9 errors/bp (<30 errors 145 
per diploid genome), two orders of magnitude lower than the BotSeqS error rate and the 146 
somatic mutation load of most human tissues studied to date. Analysis of insertions and 147 
deletions (indels) also revealed an indel error rate <3 x 10-9 errors/bp (Methods, Extended 148 
Data Fig. 5c, Supplementary Note 8). 149 
 150 
The extremely low error rate of NanoSeq, in the nano range, enables the reliable detection of 151 
somatic mutations in single DNA molecules, opening the door to the study of somatic 152 
mutations in any tissue or cell population. We take advantage of this unprecedented ability to 153 
study non-dividing cells across four tissues, addressing two elusive questions in the field of 154 
somatic mutagenesis: the difference in mutation rates between stem cells and terminally-155 
differentiated cells in mitotically-active tissues, and the rates and patterns of mutation in post-156 
mitotic tissues. 157 
 158 
Mutation burden in stem and differentiated cells 159 
 160 
Due to technical limitations, most of our knowledge of somatic mutagenesis is restricted to 161 
stem or proliferating cells. Since stem cells are believed to be better protected against 162 
mutations25, differentiated cells could conceivably have higher mutational loads and 163 
undescribed mutational signatures14. 164 
 165 
We first addressed this question in the haematopoietic system, comparing mature 166 
granulocytes to haematopoietic stem and multipotent progenitor cells (HSC/MPPs) 167 
(Methods). The haematopoietic system is organised hierarchically, with a heterogeneous 168 
pool of slow-cycling stem cells sustaining the production of large numbers of differentiated 169 
cells through the extensive proliferation of intermediate progenitor cells (Fig. 2a). HSCs are 170 
estimated to divide around once a year and conservative estimates suggest that an average of 171 
over 28 cell divisions must separate stem cells from differentiated cells to explain the 172 
production of ~1014 mature cells per year (Fig. 2a, Supplementary Note 9). As a result, a 173 
considerably higher mutation burden and mutational signatures associated with the 174 
proliferation of progenitors may be expected in granulocytes. 175 
 176 
We used NanoSeq to sequence 18 samples of granulocytes from 9 healthy donors, ranging 177 
from 20 to 80 years of age (Supplementary Table 1, 2). We compared these data to standard 178 
whole-genome sequencing of 60 single-cell derived HSC/MPPs colonies from 6 donors 179 
(Extended Data Fig. 6a, Supplementary Table 1, 2) and published data from 110 colonies 180 
from one donor26 (Methods). These data revealed remarkably similar mutation burdens in 181 
terminally-differentiated granulocytes and HSC/MPPs (Fig. 2b). Linear mixed-effect 182 
regression yielded indistinguishable slopes for HSC/MPPs colonies and granulocytes 183 
(P=0.92), with a joint estimate of ~19.9 mutations/year (CI95% 18.3-21.4, Methods, 184 
Supplementary Table 8). The excess of mutations in granulocytes over HSC/MPPs was 185 
estimated to be ~51 mutations and not significantly different from zero (CI95%: -14-120, 186 
P=0.13, Methods, Supplementary Table 8). Their mutational spectra were also largely 187 
similar (cosine similarity 0.98, Fig. 2c).  188 
 189 
The observation that a considerable increase in cell divisions does not cause a proportional 190 
increase in mutation burden suggests that replication errors cannot be responsible for more 191 
than a small minority of mutations in HSC/MPPs (Supplementary Note 9). A caveat for this 192 
comparison is that HSC/MPP colonies successfully grown in vitro may not reflect the 193 
mutation rate of the more quiescent HSCs responsible for long-term maintenance of the 194 
haematopoietic system. However, a similar conclusion can be drawn from the granulocyte 195 
data alone. The strong linear relationship with age and the small intercept for granulocytes 196 
alone (142.1 mutations, CI95%: -115.3-414.2, compared to the slope of ~19.8 197 
mutations/year) suggests that the majority of the mutations observed in adult granulocytes 198 
accumulated in the stem cells responsible for long-term maintenance, and that only a small 199 
minority of mutations are accrued during transient proliferation and terminal differentiation 200 
(Supplementary Note 9). 201 
 202 
To extend the comparison of stem cells and differentiated cells to another tissue with a well-203 
understood stem cell organisation, we studied colonic epithelium. Estimates of the somatic 204 
mutation rate in colonic stem cells are available from whole-genome sequencing of clonal 205 
organoids derived from single Lgr5+ cells10 and from sequencing single laser-microdissected 206 
colonic crypts6, which over time become clonally derived from a single stem cell27. For three 207 
previously-studied donors we compared standard whole-genome sequencing of 208 
microdissected colonic crypts6 to NanoSeq data from single crypts or groups of crypts 209 
(Extended Data Fig. 6b, c). This revealed similar estimates of mutation burden, despite the 210 
time lag to clonality in standard sequencing of colonic crypts (Fig. 2d). Mutation burden and 211 
signatures from differentiated cells in colonic epithelium were consistent with those found by 212 
previous studies on colonic stem cells, with a dominance of SBS1, SBS5 and, in some 213 
donors, a colibactin signature28 (Fig. 2e and Extended Data Fig. 6d). 214 
 215 
Overall, NanoSeq data on granulocytes and colonic epithelium yielded similar mutation 216 
burdens and signatures to their corresponding stem cells. While larger studies will be needed 217 
to identify subtler differences and to address this question in other cell types, these results 218 
provide an early view into the somatic mutation landscape of two differentiated cell types. 219 
 220 
Mutagenesis in neurons and smooth muscle 221 
 222 
Cortical neurons are a prime example of a post-mitotic tissue. This makes them a key cell 223 
type to study somatic mutagenesis in the absence of cell division, but also inaccessible to 224 
traditional sequencing methods. Despite the technical challenges impeding progress, somatic 225 
mutations in neurodegeneration have attracted considerable interest1,12,13,29. 226 
 227 
We applied NanoSeq to frontal cortex neurons from 8 healthy donors and 9 Alzheimer's 228 
disease (AD) patients (Supplementary Table 1), using nuclei sorting with the NeuN 229 
neuronal marker (Methods, Extended Data Fig. 7a). These data revealed a linear 230 
accumulation of 17.1 substitutions (linear regression, CI95%:13.7-20.5) and 2.5 indels 231 
(CI95%:1.7-3.3) per year, approximately constant throughout life (Fig. 3a, b, 232 
Supplementary Table 8). This confirms that mutations accumulate in a clock-like fashion in 233 
cortical neurons, in the absence of cell division, consistent with observations from single-cell 234 
sequencing13. 235 
 236 
A previous study using SNP-phased error-corrected single-cell sequencing reported three 237 
signatures in neurons, one that increased linearly with age and two that did not13. The 238 
spectrum found by NanoSeq and the mutation rate per year closely resemble the age-239 
associated signature in that study (cosine similarity 0.96; Fig. 3a, c and Extended Data Fig. 240 
7b, c). The two other signatures, responsible for around 72% of all mutations reported in the 241 
study (Extended Data Fig. 7d), appear exclusively in single-cell data and likely derive from 242 
amplification errors or transient DNA damage. Consistent with this possibility, the dominant 243 
signature in single-neuron data closely resembles a single-cell-specific signature reported in 244 
vitro16 (cosine similarity 0.97, Extended Data Fig. 7b). 245 
 246 
To better understand the mutational processes active in post-mitotic neurons, we performed 247 
signature decomposition on NanoSeq data from neurons, granulocytes, colonic crypts and 248 
smooth muscle (described below). Three signatures were extracted (Fig. 3e): signatures A 249 
and C imperfectly resembled SBS5 (cosine similarity 0.80) and SBS16 (0.78), respectively, 250 
while signature B closely matched SBS1 (C>T changes at CpG dinucleotides, cosine 251 
similarity 0.96). It is conceivable that SBS5, which appears to be a ubiquitous signature in 252 
normal tissues and cancer genomes30, reflects a collection of co-occurring processes, rather 253 
than a single mutational process, leading to some differences across tissues. The observation 254 
in post-mitotic neurons of signatures resembling SBS5 and SBS16 suggests that these 255 
common processes, whose aetiologies remain poorly understood, can occur independently of 256 
cell division. 257 
 258 
The mutational spectra from neurons (Fig. 3c, d) showed several interesting features. T>C 259 
substitutions at ApT sites appear enriched in neurons and show strong transcriptional strand 260 
biases (Extended Data Fig. 8b, c). Signature B (SBS1), which is believed to be caused by 5-261 
methylcytosine deamination and fixed during DNA replication, accumulates at a low rate 262 
with age in neurons (2.5 substitutions per year, linear regression CI95% 0.9-4.1, P = 0.005; 263 
Extended Data Figs. 7e and 9a, b). This suggests that 5-methylcytosine deamination can be 264 
fixed in both DNA strands without cell division, possibly by DNA repair. Neurons also have 265 
a higher proportion of indels than other tissues, with an unusual enrichment of indels longer 266 
than 1bp in highly-expressed genes, a pattern that resembles a mutational process recently 267 
described in cancer genomes31 (Fig. 3d, f and Extended Data Fig. 9c, d). In contrast to other 268 
somatic tissues, neurons did not exhibit a clear association between expression levels and 269 
substitution rates across genes (Fig. 3g) and the enrichment of mutations in heterochromatin 270 
was weaker (Fig. 3h and Extended Data Fig. 8a). 271 
 272 
Although the difference is small, AD donors showed a slightly lower substitution rate than 273 
healthy donors (linear regression, 17.6 (CI95%:15.0-20.2) vs 19.9 (CI95% 16.8-23.0) 274 
substitutions/year, P = 0.0029) (Fig. 3i, Extended Data Fig. 7e, Supplementary Table 8). 275 
This could simply reflect differences in the patient cohorts or be related to the pathogenesis 276 
of the disease, for example due to differences in metabolism or variable death rates across 277 
subpopulations of neurons in AD. Studies with larger cohorts will be required to validate and 278 
explain this observation. 279 
 280 
To extend these analyses to another tissue not amenable to standard sequencing methods, we 281 
studied smooth muscle. Visceral smooth muscle cells are believed to divide infrequently in 282 
normal conditions32. We used laser microdissection of histological sections of bladder and 283 
colon to collect smooth muscle from 10 donors (Supplementary Table 1, 2, Extended Data 284 
Figs. 6b and 10a). As expected for a polyclonal tissue, standard whole-genome sequencing 285 
detected few mutations and at low allele frequencies in these samples (Extended Data Fig. 286 
10b, c, Methods). In contrast, NanoSeq revealed that the substitution and indel burdens 287 
increase linearly with age, with ~20.7 substitutions per year per diploid genome 288 
(CI95%:13.7-28.0) and ~1.3 indels per year (95%:0.4-2.3) (Fig. 3j,k, Supplementary Table 289 
8). Despite their different anatomical origin, smooth muscle cells from the bladder and colon 290 
walls showed relatively similar mutation rates. Overall, the mutational spectrum of smooth 291 
muscle shared some similarities with that of granulocytes and neurons (Figs. 3l-n and 1c), 292 
with all three signatures (A-C) accumulating linearly with age (Extended Data Fig. 7f). The 293 
spectra also resemble that of skeletal muscle satellite cells, studied by in vitro expansion11 294 
(Supplementary Note 10).  295 
 296 
Altogether, granulocytes, smooth muscle and neurons showed more limited variation in 297 
mutation rate and spectra across individuals than has been observed in epithelia exposed to 298 
exogenous mutagens, such as skin3, colon6 (Fig. 2c), bronchus33 or bladder8,34. This suggests 299 
that the variation in endogenous mutagenesis across individuals is modest, at least in the 300 




Building on duplex sequencing and BotSeqS, we have developed a sequencing protocol with 305 
error rates in single DNA molecules under 5 errors per billion sites. This rate enables the 306 
study of mutation rates and signatures in any human tissue or cell population. 307 
 308 
Most of our current knowledge of somatic mutagenesis is restricted to mitotically-active 309 
cells. We have exploited the ability to sequence any cell type to study the mutational 310 
landscape of non-dividing cells in mitotically-active and inactive tissues. A remarkable 311 
observation that emerges from these data is that somatic mutation rates vary modestly (~2-3 312 
fold) across a diverse range of somatic cell types, largely independently of cell division rates 313 
(Fig. 3o, p, Supplementary Note 9). Indeed, similar mutation rates are found in non-314 
dividing cortical neurons, in smooth muscle and in blood; or in colonic epithelium, which 315 
divides every few days, and in mostly quiescent hepatocytes10 or urothelial cells (Fig. 3o, p). 316 
 317 
DNA replication and cell division have long been assumed to be major sources of somatic 318 
mutations, either due to DNA polymerase errors or the fixation of unrepaired damage during 319 
replication35. However, the linear accumulation of somatic mutations in post-mitotic neurons, 320 
with similar rates and signatures to some mitotically-active tissues, indicates that dominant 321 
mutational processes can occur independently of cell division. These mutations may result 322 
from the interplay between endogenous DNA damage and repair that cells are engaged in at 323 
all times. The similar mutation burden and signatures in granulocytes and in the stem cells 324 
responsible for long-term maintenance of blood, despite a different divisional load, could also 325 
be consistent with a time-dependent rather than a division-dependent accumulation of 326 
somatic mutations during haematopoiesis. Altogether, division-independent mutational 327 
processes may play a larger role in adult mutagenesis than it is commonly assumed. 328 
 329 
In addition to enabling studies on somatic mutagenesis in any tissue, the ability to accurately 330 
detect mutations in single molecules of DNA has wider applications. NanoSeq could be used 331 
for mutagenesis screens and in vitro studies, exposing cell cultures or experimental models to 332 
different mutagens and quantifying mutagenesis across the genome and over time, without 333 
the need of single-cell bottlenecks36,37. Sonication followed by exonuclease digestion opens 334 
the door to targeted applications, to study the landscape of driver or pathogenic mutations in 335 
polyclonal samples, across tissues and conditions. Being insensitive to clonality, NanoSeq 336 
can also be used to efficiently and accurately quantify somatic mutation rates and signatures 337 
in non-invasive tissue samples, enabling studies of somatic mutagenesis in large-scale 338 
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Figure legends 436 
 437 
Figure 1 | BotSeqS and NanoSeq sequencing protocols. a, Duplex sequencing protocol. b, 438 
BotSeqS mutation burden estimates in cord blood granulocytes compared to 100 single-cell 439 
derived blood colonies from two donors. c, BotSeqS and NanoSeq substitution profiles for 440 
cord blood granulocytes, and cosine similarities (Methods) with the cord blood colonies 441 
profile. d, Substitution imbalances are present in standard BotSeqS protocols but absent from 442 
NanoSeq (Extended Data Figs. 1 and 2 show further details for a library of granulocytes 443 
from a 59-year-old donor). Imbalances were tested with a binomial test (p of 0.5) and p-444 
values were corrected with Benjamini and Hochberg's FDR method. e, Standard BotSeqS 445 
(top) and NanoSeq protocols (bottom) for library preparation. f, g, NanoSeq mutation burden 446 
estimates for cord blood granulocytes (S1/PD48442, n=6 libraries; S2/PD47269, n=1) and 447 
sperm from a 21-year-old donor (n=7) compared to blood colonies and sperm estimates, 448 
respectively; b, f, g, Bars show point estimates and their 95% Poisson confidence intervals. b, 449 
f, Box plot shows the interquartile range, median, 95% confidence interval for the median, 450 
and outliers as grey dots. f, The mean and its 95% confidence interval are shown in red. 451 
 452 
 453 
Figure 2 | Mutation in stem and differentiated cells. a, Schematic representation of the 454 
hematopoietic lineage showing which cell types and donors were analysed.  b, Substitutions 455 
per cell for donors of different ages, comparing granulocytes and single-cell derived blood 456 
colonies. NanoSeq estimates for granuloctyes (red dots) obtained for one library per donor 457 
except for donors of ages 54 (n=2), 63 (n=2), and 59 (n=5). Standard sequencing estimates 458 
are shown as box plots and based on 10 colonies per donor, except for the 59-year-old 459 
(n=110) and cord blood (n=100). c, Granulocytes and blood colonies substitution profiles and 460 
their cosine similarity (Methods) for the 59-year-old donor. d, Burden estimates in colonic 461 
crypts from three donors, comparing standard methods (box plots) and NanoSeq (red dots; 462 
n=3, 2 and 2 libraries per donor); e, Accumulation of substitutions throughout life in colonic 463 
crypts from five donors, excluding substitutions attributed to the episodic colibactin 464 
signature. b, d, Dots and lines show point estimates and their corresponding 95% Poisson 465 
confidence intervals, respectively. b, d, Box plots show the interquartile range, median, 95% 466 
confidence interval for the median, with outliers as grey dots. b, e, Linear mixed regression 467 
models for granulocytes (red dashed line), blood colonies (dark cyan), and colonic crypts 468 
(black), with 95% confidence intervals calculated through parametric bootstrapping 469 
(Methods). Regression intercepts and slopes are provided in Supplementary Table 8.  470 
 471 
Figure 3 | Mutation landscape in neurons and smooth muscle. a, b, Accumulation of 472 
substitutions and indels in neurons throughout life, including healthy (n=8) and Alzheimer's 473 
disease (n=9) donors. c, d, Substitution and indel spectra in neurons; a description of each 474 
type of indel can be found in Extended Data Fig. 5d. e, Signature decomposition. f, g, Indel 475 
and substitution rates in genes in the whole cohort by level of expression. h, Substitution 476 
rates in transcribed and quiescent/heterochromatin DNA across different cell types (spectra in 477 
Extended Data Fig. 8a). i, Contribution of signatures A, B and C in neurons.  j, k, 478 
Substitutions and indels per cell in smooth muscle from 10 donors spanning different ages 479 
(n=2 libraries for donors aged 54 and 68). l, m, Substitution and indel spectra in smooth 480 
muscle. n, Exposure to signatures A, B and C in smooth muscle samples. o, p, Substitution 481 
and indel accumulation per year across different cell types; 95% confidence intervals 482 
estimated through simple (neurons and urothelium) or mixed effect (rest) linear regression 483 
with intercept=0; vertical lines show regression 95% confidence intervals. a, b, f, g, h, j, k, 484 
vertical lines show Poisson 95% confidence intervals. a, b, Linear regression model as 485 
dashed lines, showing 95% confidence interval as grey areas. j, k, Linear mixed effect 486 
regressions as dashed lines, showing 95% confidence intervals obtained through parametric 487 
bootstrapping (Methods) as grey areas. Regression results with free or zero intercept are 488 





Sample collection and ethics 494 
 495 
All samples were collected with informed consent from all human research participants or 496 
their families. The haematological samples in the study were obtained from the Cambridge 497 
Blood and Stem Cell Biobank, the Cambridge Biorepository for Translational Medicine, and 498 
the Cambridge Bioresource (REC references: 07-MRE05-44, 18/EE/0199, 15/EE/0152 - 499 
NRES Committee East of England - Cambridge South). Sperm samples were collected under 500 
REC ethics approval EC04/015, London - Westminster REC; 16/NE/003, NRES Committee 501 
North East-Newcastle and North Tyneside 1. Colon and bladder tissue were collected by the 502 
Cambridge Biorepository for Translational Medicine (REC reference: 15/EE/0152 NRES 503 
Committee East of England – Cambridge South). Frozen biopsies of frontal cortex from 504 
healthy and Alzheimer’s disease donors were collected by the Cambridge Brain Bank 505 
(Supplementary Tables 1, 2; REC ethics approval: 10/H0308/56, East of England, 506 
Nottingham). 507 
 508 
Granulocytes and HSC/MPP colonies: sorting, colony growth and mutation calling 509 
 510 
We use two different terms to refer to colonies derived from haematopoietic stem cells (HSC) 511 
or progenitor cells, depending on the membrane markers used for cell sorting: HSPCs, which 512 
refer to CD34+ pools, and HSC/MPPs, which refer to CD34+ CD38- CD45RA- cells.  513 
 514 
A sample of granulocytes from a 59-year-old male donor (PD43976_59yo) from whom 110 515 
HSPC colonies were available26 was used for initial validation of the BotSeqS and NanoSeq 516 
protocols (Supplementary Tables 1, 2). To estimate the NanoSeq error rate, cord blood 517 
granulocytes from two neonatal donors were sequenced by NanoSeq and the mutation 518 
burdens and spectra compared to those from 50 HSC/MPP colonies per donor. For the 519 
comparison of differentiated and stem cells, NanoSeq data from granulocytes from 9 donors 520 
of different ages were compared to standard sequencing of single-cell derived HSC/MPP 521 
colonies from 6 donors (10 HSC/MPP colonies per donor) and 110 HSPC colonies already 522 
available from a 59-year-old donor26. These 110 HSPC included 67 HSC/MPPs, 32 523 
megakaryocyte–erythrocyte progenitors (MEP), 7 granulocyte–macrophage progenitors 524 
(GMP) and 4 common myeloid progenitors (CMP).  525 
 526 
For PD43976_59yo, HSPC colonies were grown and mutations called as described in Lee Six 527 
et al.26. For the remaining donors, whole blood was diluted with PBS and mononuclear cells 528 
(MNC) were isolated using lymphoprepTM (STEMCELL Technologies) density gradient 529 
centrifugation. The MNC fraction was then removed to a fresh tube, leaving behind the red 530 
cell pellet, which also contained the granulocyte fraction. The MNC fraction was depleted of 531 
red blood cells by a single 15 min incubation with RBC lysis buffer (BioLegend) at 4oC.  532 
Granulocytes were purified from the red cell pellets using 3 incubations (for 20 mins/10 533 
mins/10 mins respectively) with RBC lysis buffer (BioLegend) at room temperature.  CD34+ 534 
selection of peripheral blood and cord blood samples was undertaken using the EasySep 535 
human whole blood CD34 positive selection kit (STEMCELL Technologies) as per the 536 
manufacturer’s instructions. Bone marrow samples did not undergo CD34+ selection prior to 537 
sorting. 538 
 539 
MNC or CD34 enriched samples were centrifuged and resuspended in PBS/3%FBS 540 
containing an antibody panel consisting of (antibody/fluorochrome): CD3/FITC (1:500), 541 
CD90/PE (1:50), CD49f/PECy5 (1:100), CD38/PECy7 (1:100), CD19/A700 (1:300), 542 
CD34/APC Cy7 (1:100), CD45RA/BV421 (1:100), and Zombie/Aqua (1:2000). 543 
 544 
Cells were stained (30 minutes at 4oC) in the dark before washing, centrifugation (500 x g at 545 
room temperature) and resuspension in PBS/3%FBS for cell sorting. Index sorting of 546 
‘HSC/MPP pool’ cells was performed on a BD AriaIII Cell Sorter (BD Biosciences) at the 547 
NIHR Cambridge BRC Cell Phenotyping Hub, as per the gating structure in Extended Data 548 
Fig. 6a (CD34+, CD38- and CD45RA-). 549 
 550 
‘HSC/MPP pool’ cells were single-cell sorted into Nunc 96 well flat-bottomed TC plates 551 
(ThermoFisher) containing 100 μl supplemented StemPro media (Stem Cell Technologies). 552 
MEM media contained StemPro Nutrients (0.035%, Stem Cell Technologies), L-Glutamine 553 
(1%, ThermoFisher), Penicillin-Streptomycin (1%, ThermoFisher) and cytokines (SCF, 100 554 
ng/ml; FLT3, 20 ng/ml; TPO, 100 ng/ml; EPO 3 ng/ml; IL-6, 50 ng/ml; IL-3, 10 ng/ml; IL-555 
11, 50 ng/ml; GM-CSF, 20 ng/ml; IL-2 10 ng/ml; IL-7 20 ng/ml; lipids 50 ng/ml) to promote 556 
differentiation towards Myeloid/Erythroid/Megakaryocyte (MEM) and NK lineages. Manual 557 
assessment of colony growth was made at 14 days. Colonies were topped up with an 558 
additional 50 μL MEM media on day 15 if the colony was ≥1/4 size of well. Following 21 ± 559 
2 days in culture, colonies were selected by size criteria. Colonies ≥ 3000 cells in size were 560 
harvested into a U bottomed 96 well plate (ThermoFisher). Plates were then centrifuged (500 561 
x g for 5 minutes), media was discarded, and the cells were resuspended in 50 µl PBS prior to 562 
freezing at -80ºC. Colonies < 3000 cells but > 200 cells in size were harvested into 96 well 563 
skirted LoBind plates (Eppendorf) and centrifuged (800 x g for 5 min). Supernatant was 564 
removed to 5-10 μL using an aspirator prior to DNA extraction on the fresh cell pellet. 565 
 566 
DNA extraction was performed using the DNeasy 96 blood and tissue plate kit (Qiagen) for 567 
larger HSC colonies, or the Arcturus Picopure DNA Extraction kit (ThermoFisher) for 568 
smaller HSC colonies. Both kits were used as per the manufacturer’s instructions. Extracted 569 
DNA (1-5ng) from each colony was processed using a recently developed low-input 570 
enzymatic fragmentation-based library preparation method38. All samples were subjected to 571 
whole genome sequencing at 8-35X coverage on either the HiSeq X or the NovaSeq 572 
platforms (Illumina) to generate 150 bp paired-end reads. BWA mem was used to align 573 
sequences to the human reference genome (NCBI build37). 574 
 575 
Sperm samples 576 
 577 
DNA was extracted from sperm samples from two donors, aged 21 and 73 years, and 578 
sequenced using the NanoSeq protocol. Because of the low mutation burden of the germline, 579 
we sequenced 7 separate aliquots of sperm DNA from the 21-year-old donor to estimate the 580 
error rate of the NanoSeq protocol (Supplementary Tables 1, 2). 581 
 582 
Laser microdissection of colonic crypts and bladder/colon smooth muscle  583 
 584 
Colon and bladder biopsies were obtained from deceased organ donors (ranging in age from 585 
25 to 78; Supplementary Table 1) at the time of organ donation. Different microbiopsies 586 
from these specimens have been used in previously published studies6,34,39. 587 
 588 
Colon biopsies were fresh frozen at the time of collection and stored at -80 ˚C. The colon 589 
biopsies subsequently underwent formalin-free fixation for 24 hours in PAXgene Tissue Fix 590 
containers (PreAnalytiX, Hombrechtikon, Switzerland) before being transferred to PAXgene 591 
STABILIZER solution (PreAnalytiX). Bladder biopsies underwent formalin-free fixation at 592 
the time of collection and were stored at -20 ˚C 38. 593 
 594 
Prior to laser-capture microdissection, samples were processed, embedded in paraffin and 595 
sectioned as described previously34. Microbiopsies were dissected using an LMD7 596 
microscope (Leica Microsystems). Examples of microdissected regions for both specimen 597 
types can be found in Extended Data Figs. 6 and 10. Proteolysis of isolated regions was 598 
performed using an Arcturus PicoPure DNA Extraction Kit (Thermo Fisher Scientific, 599 
Waltham, MA, USA). Cell lysate was stored at -20 °C prior to library preparation. 600 
 601 
Neuron nuclei sorting from frontal cortex samples 602 
 603 
Neuronal nuclei were isolated, stained and extracted from the frontal cortex samples as per 604 
Krishnaswami et al.40 using frozen biopsies of frontal cortex from eight healthy and nine 605 
Alzheimer’s disease donors. Briefly, small cuts of 1-2 mm were taken from fresh frozen 606 
samples. Dounce homogenisation was then used to free nuclei before filtration, density 607 
centrifugation and immunostaining. Samples were stained using DAPI (Thermo Fisher, 608 
D1306) and Milli-Mark™ Anti-NeuN-PE Antibody (1:500; MilliPore, FCMAB317PE). The 609 
immunostained samples were then sorted using FACS as per the gating strategy in Extended 610 
data Fig. 7a. 15,000 nuclei were collected into 20 μl Arcturus PicoPure DNA Extraction Kit 611 
(Thermo Fisher Scientific) before undergoing digestion. Nuclear lysate was then stored at -612 
20ºC prior to library preparation. 613 
 614 
The distributions of NeuN-PE intensities in most samples revealed a bimodal distribution. As 615 
a quality control, we fitted a mixture of two Gamma distributions to the NeuN-PE intensities 616 
for every samples. Only samples with 10-fold (1 log10 unit) separation between the mean of 617 
both peaks were considered for analysis, which led to the exclusion of an outlier sample. 618 
 619 
BotSeqS and NanoSeq library preparation protocols 620 
 621 
BotSeqS libraries shown in Fig. 1 and Extended Data Fig. 3 were prepared as follows: DNA 622 
was sheared to 450 bp using a Covaris. DNA was cleaned up using a 2.5X Ampure XP 623 
(Beckman Coulter) bead ratio. DNA was eluted in 12 µL NFW. 10 µL of the elution product 624 
were taken into the ligation reaction consisting in addition of 3.74 µL NEBuffer 4, 3.74 µL 625 
10 mM ATP, 0.33 µL xGen Duplex Seq Adapters (IDT 1080799), 0.56 µL T4 DNA ligase 626 
(NEB M0202L) and 19.03 µL NFW. The reaction was incubated at 20 ºC for 20 min. The 627 
DNA was cleaned-up using 37.4 µL Ampure XP beads and DNA was eluted in 50 µL NFW. 628 
Libraries were quantified (qPCR) and amplified following the NanoSeq protocol. For the 629 
BotSeqS data on granulocytes from a 59-year-old donor, shown in Extended Data Figs. 1 and 630 
2, we used an earlier implementation of the protocol. 10 ng of sonicated DNA was end-631 
repaired and ligated using the NEBNext Ultra II kit (New England Biolabs) including 0.66 µl 632 
1.5 µM xGen Duplex Seq Adapters - Tech Access (Integrated DNA Technologies, IDT: 633 
1080799). 634 
 635 
NanoSeq libraries were prepared as follows: 10 ng of genomic DNA or LCM cut sections in 636 
20 µl buffer were purified using 100 µl of a 50:50 water and AMPure XP bead mixture and 637 
eluted in 20 µl nuclease free water. 20 µl of the bead suspension was taken forward into an 638 
on-bead fragmentation reaction. Fragmentation occurred in a final volume of 25 µl including 639 
2.5 µl 10x CutSmart buffer (500 mM Potassium Acetate, 200 mM Tris-acetate, 100 mM 640 
Magnesium Acetate, 1 mg/ml BSA, pH 7.9 at 25°C), 0.5 µl 5 U/µl HpyCH4V 641 
(Supplementary Note 2), and 2 µl NFW. Fragmentation reactions were incubated at 37 ºC 642 
for 15 min, purified with 2.5x AMPure XP beads and resuspended in 15 µl nuclease-free 643 
water. Fragmented DNA was A-tailed in 15 µl reactions including 10 µl fragmentation 644 
product, 1.5 µl 10x NEBuffer 4 (500 mM Potassium Acetate, 200 mM Tris-acetate, 100 mM 645 
Magnesium Acetate, 10 mM DTT, pH 7.9 at 25°C), 0.15 µl 5 U/µl Klenow fragment (3′→5′ 646 
exo-, New England Biolabs), either 1.5 µl 1 mM dATP or 1.5 µl 1 mM equimolar 647 
dATP/ddBTPs (Supplementary Note 3), and 1.85 µL NFW. Reactions were incubated at 37 648 
ºC for 30 mins. The 15 µl A-tailing reaction product was added to 22.4 µl ligation mix, which 649 
consisted of 2.24 µl 10x NEBuffer 4, 3.74 µl 10 mM ATP, 0.33 µl 15 µM xGen Duplex Seq 650 
Adapters (IDT: 1080799), 0.56 µl 400 U/µl T4 DNA ligase (New England Biolabs), and 651 
15.53 µl NFW. Reactions were incubated at 20 ºC for 20 min and subsequently purified with 652 
1x AMPure XP beads and resuspended in 50 µl of nuclease free water.  653 
 654 
Mung Mean NanoSeq libraries were prepared as follows: DNA was sheared to an average 655 
size of 450 bp using focused ultrasonication (Covaris 644 LE220). Sheared DNA was 656 
quantified and 50 ng were used as input per reaction. Mung Bean nuclease (NEB: M0250S) 657 
was diluted to 1U, 0.5U or 0.25U/ µL in 1X Mung Bean nuclease buffer. The Mung Bean 658 
reaction was carried out in a final volume of 30 µL including 2.9 µL 10X Mung Bean 659 
nuclease buffer, 1 µL diluted Mung Bean nuclease, 10 µL DNA and 16.1 µL NFW. The 660 
reaction was incubated at 30 ºC for 30 min. Then, 1 µL 0.3% SDS was added and the reaction 661 
was cleaned up using 77.5 µL Ampure XP beads. Samples were eluted in 12 µL NFW. 10 µL 662 
was used as input into a phosphorylation reaction by adding 1.5 µL NEBuffer 4 (NEB 663 
B7004S), 1.5 µL 10 mM ATP (Fisher Scientific 10304340), 0.6 µL T4 Polynucleotide 664 
Kinase (NEB M0201S) and 1.4 µL NFW. The reaction was incubated at 37 ºC for 30 min. 13 665 
µL were taken forward into an A-tailing reaction, adding 0.2 µL NEBuffer 4, 1.5 µL 1 mM 666 
dATP/ddBTP (NEB N0440S/GE Healthcare 27204501), 0.15 µL Klenow fragment (3'→5' 667 
exo-, NEB M0212L) and 0.15 µL NFW. The reaction was incubated at 37 ºC for 30 min. The 668 
whole 15 µL were taken into the ligation reaction mix, which consisted of 2.24 µL NEBuffer 669 
4, 3.74 µL 10 mM ATP, 0.33 µL xGen Duplex Seq Adapters (IDT 1080799), 0.56 µL T4 670 
DNA ligase (NEB M0202L) and 15.53 µL NFW. The reaction was incubated at 20 ºC for 20 671 
min. The DNA was cleaned-up using 37.4 µL Ampure XP beads and DNA was eluted in 50 672 
µL NFW. Libraries were quantified and amplified following the NanoSeq protocol. 673 
 674 
DNA quantification, dilution and PCR amplification 675 
 676 
DNA was quantified by qPCR using a KAPA library quantification kit (KK4835). The 677 
supplied primer premix was first added to the supplied KAPA SYBR FAST master mix. In 678 
addition, 20 µl of 100 µM NanoqPCR1 primer (HPLC: 5′-ACACTCTTTCCCTACACGAC-679 
3′) and 20 µl of 100 µM NanoqPCR2 primer (HPLC: 5′-GTGACTGGAGTTCAGACGTG-680 
3′) were added to the KAPA SYBR FAST master mix. Samples were diluted 1 in 500 using 681 
nuclease-free water and reactions were set up in a 10 µl reaction volume (6 µl master mix, 2 682 
µl sample/standard, 2 µl water) in a 384 well plate. Samples were run on the Roche 480 683 
Lightcycler and analysed using absolute quantification (2nd Derivative Maximum Method) 684 
with the high sensitivity algorithm. nM (fmol/µl) was determined as follows: mean of sample 685 
concentration x dilution factor (500) x 452/573/1000 (where 452 is the size of the standard in 686 
bp and 573 is the proxy for the average fragment length of the library in bp), and multiplied 687 
by an adjustment factor of 1.5. Samples were diluted to the desired fmol amount (typically 688 
0.3 fmol for a 15x run) in 25 µl using nuclease free water. 689 
 690 
Libraries were subsequently PCR amplified in a 50 µl reaction volume comprising of 25 µl 691 
sample, 25 µl NEBNext Ultra II Q5 Master Mix and UDI containing PCR primers (dried). 692 
The reaction was cycled as follows: step1: 98 ºC 30 seconds, step2: 98 ºC 10 seconds, step3: 693 
65 ºC 75 seconds, step4: return to step2 13 times, step5: 65 ºC for 5 min, step6: hold at 4 ºC. 694 
The number of PCR cycles is dependent upon the input: 0.1 fmol = 16 cycles, 0.3 fmol = 14 695 
cycles, 0.6 fmol = 13 cycles, 5 fmol = 10 cycles. 696 
 697 
The PCR product was subsequently cleaned up using two consecutive 0.7x AMPure XP 698 
clean-ups. Each sample was quantified using the AccuClear Ultra High Sensitivity dsDNA 699 
Quantification kit (Biotium) and pooled. Libraries were sequenced on Illumina sequencing 700 
platforms e.g. NovaSeq using 150 paired-end reads.  701 
 702 
Library dilution and sequencing efficiency 703 
 704 
The efficiency and cost-effectiveness of duplex sequencing depends on optimising the 705 
duplicate rate to maximise the number of read bundles (defined as a family of PCR 706 
duplicates) with at least 2 duplicate reads from each original strand. Too high duplicate rates 707 
result in few read bundles of unnecessarily large sizes, whereas too low duplicate rates result 708 
in many read bundles with few having two or more read pairs from each strand. 709 
 710 
To maximise the efficiency of the protocol, we studied analytically and empirically the 711 
relationship between the number of DNA molecules in the library (library complexity) and 712 
the resulting duplicate rate as a function of the number of read pairs sequenced. We found 713 
that optimal duplicate rates and optimal efficiency can be ensured across a wide range of 714 
samples. If we assume negligible PCR biases, with copies from all original ligated DNA 715 
fragments represented in equimolar amounts in the amplified library, the bundle size 716 
distribution of observed reads can be modelled as a zero-truncated Poisson distribution. Let r 717 
(sequence ratio) be the ratio between the number of sequenced reads and the number of 718 
amplifiable DNA fragments in the original library. The mean read bundle size (m) can then 719 
be estimated as the mean of the zero-truncated Poisson distribution: =	  . This 720 
parameter then enables a simple estimation of the duplicate rate of a library (d, defined as the 721 
fraction of reads that are duplicate copies, and identified as reads having the same barcodes 722 
and the same 5′ and 3′ coordinates):  =	 = 	1 − = 1 −	  . 723 
 724 
We can define the efficiency of a duplex sequencing library (E) as the ratio between the 725 
number of base pairs with duplex coverage (bundles with ≥ 2 reads from both strands) and 726 
the number of base pairs sequenced. This can be modelled as: = ( ;	 )  , where the 727 
numerator is the probability of a read bundle having at least two reads from both strands (i.e. 728 
usable bundles), based on the zero-truncated Poisson distribution (denoted as P), and the 729 
denominator is the sequence investment in each read bundle (i.e. the average read bundle 730 
size). Based on this equation, we can estimate numerically that the optimal duplicate rate is 731 
~81% (Extended Data Fig. 4a, Supplementary Code) and that duplicate rates between 65-732 
90% would yield ≥80% of the maximum attainable efficiency. In terms of r, the optimum r is 733 
5.1 read pairs sequenced per original DNA fragment (ropt), with values within 2.7-9.6 734 
yielding ≥80% of the maximum efficiency. Knowing the concentration of a NanoSeq (or 735 
BotSeqS) library in fmol/μl (estimated using a qPCR reaction on an aliquot of the library), 736 
we can use ropt to calculate the volume of library that needs to be amplified to yield optimal 737 
duplicate rates (i.e. maximum duplex efficiency), as a function of the desired amount of raw 738 
sequencing: =	 	 . Here, N is the number of paired-end reads that will be 739 
sequenced and f is the number of DNA fragments per fmol of library (referring specifically to 740 
ligated and amplifiable fragments within the size selection range). Using an initial set of 741 
libraries, we compared a range of library inputs (fmol) to the estimated number of unique 742 
molecules in the library inferred from the sequencing data (using Piccard’s software). This 743 
analysis revealed that, for our choice of restriction enzyme and size selection conditions, f 744 
approximately equated to 108 fragments/fmol (Supplementary Code). 745 
 746 
Using the above equation, we can optimise the efficiency of NanoSeq independently of the 747 
input amount of DNA in a given sample. For example, ~0.3 fmols of library yield optimal 748 
duplicate rates when using 150 million 150 bp paired-end reads, which are the equivalent of 749 
~15x coverage in standard human whole-genome sequencing. ~0.6 fmol yield optimal 750 
efficiency when using 300 million reads (30x whole-genome equivalent). Note that, as 751 
predicted by the equations above, deviations ~2-fold from ropt still yield high efficiency. 752 
Using these equations, we reliably obtained near-optimal duplicate rates from a wide 753 
diversity of samples (Extended Data Fig. 4, Supplementary Table 2). Overall, we found 754 
that ~30x of standard sequencing output (~300 x 106 150bp PE reads) yielded approximately 755 
3 Gb of high-accuracy duplex coverage (a haploid genome equivalent) after application of all 756 
computational filters. 757 
 758 
Our choices of restriction enzyme and size selection restrict the coverage to ~30% of the 759 
human genome. Although the covered regions are sufficiently diverse to enable unbiased 760 
estimates of burden and signatures (Methods), applications that require full genome 761 
coverage, such as targeted sequencing, would require alternative fragmentation strategies. 762 
One option may be exonuclease blunting after sonication, instead of end repair. Nevertheless, 763 
for the study of burden and signatures, the use of restriction enzymes has two interesting 764 
advantages. First, this protocol is able to work with very low inputs of DNA. We estimated 765 
library yields for a range of input DNA amounts (Extended Data Fig. 4b) and found that the 766 
minimum DNA input required to obtain 0.3 fmol for a 15x run (corresponding to about 1.5-3 767 
Gb of effective duplex coverage) was ~1 ng of input DNA. This low-input requirement 768 
enables the application of NanoSeq to microscopic areas of tissue (as shown for colonic 769 
crypts and smooth muscle) and to rare cell populations using flow sorting. A second 770 
advantage is that, since coverage is concentrated in ~30% of the human genome, matched 771 
normal samples can be sequenced at lower cost by using undiluted NanoSeq libraries (≥3 772 
fmol of library sequenced at 8x genome equivalent is enough to provide high matched normal 773 
coverage in the 30% of informative genome). 774 
 775 
Sequencing, pre-processing and filtering of BotSeqS and NanoSeq libraries 776 
 777 
Standard sequencing matched-normal libraries were aligned to the human reference genome 778 
(GRCh37, hs37d5 build) using BWA-MEM v0.7.5a-r405 41 with default parameters. 779 
Alignments were sorted by coordinate and read duplicates were marked using biobambam2 42 780 
v2.076 bamsormadup. Matched-normal reads were filtered if marked as duplicate, 781 
supplementary, QC fail, unmapped or secondary alignments. For some samples, as described 782 
above, instead of standard whole-genome sequencing, we used undiluted NanoSeq libraries 783 
(typically ~5 fmol) as matched normals, reducing the costs of sequencing matched normal 784 
samples. 785 
 786 
NanoSeq and BotSeqS libraries were sequenced using 150 bp paired-end reads, on 787 
HiSeq2500, HiSeqX and NovaSeq platforms.  788 
 789 
NanoSeq sequencing reads begin with adapter sequences: NNNT or NNNXT for BotSeqS 790 
libraries and NNNTCA or NNNXTCA for HpyCH4V libraries (HpyCH4V cuts at TGCA 791 
motifs). NNN is a random three nucleotide barcode, T is the adapter overhang and X is a 792 
‘spacer’ nucleotide designed to increase nucleotide diversity in the sequencing run. We used 793 
a custom Python script to process demultiplexed fastq files by extracting the three-nucleotide 794 
barcode, clipping remaining adapter bases (2 bases for BotSeqS and 4 bases for NanoSeq 795 
libraries) and appending barcode sequences to the fastq header. Barcodes with non-canonical 796 
bases (not A, C, G or T) were filtered out. Reads were aligned to hs37d5 using bwa mem 797 
(v0.7.5a-r405), using the -C option to append barcode sequences to alignments. Alignments 798 
were sorted by coordinate, duplicates were marked, and reads were annotated with read 799 
coordinate, mate coordinate and optical duplicate auxiliary tags using biobambam2 v2.076 800 
bamsormadup and bammarkduplicatesopt (optminpixeldif=2500). Reads were filtered when 801 
they were not marked as proper-pairs or were marked as optical duplicate, supplementary, 802 
QC fail, unmapped or secondary alignments. Each read was marked with an auxiliary tag 803 
comprised of reference name, sorted read and mate fragmentation breakpoints, forward and 804 
reverse read barcodes, and read strand. 805 
 806 
Consensus base quality scores 807 
 808 
Bayes’ theorem was used to compute the posterior probability of each base call B given the 809 
pileup of reads D from one strand of a template molecule at one genomic position. There are 810 
four possible genotypes i ∈ (A, C, G, T). The posterior probability is calculated using: 811 
 812 ( | ) = ( ) ( | )	∑ ( ) ( | ) 
 813 
Under a uniform prior, where any of the four possible genotypes are equally likely, the 814 
equation can be simplified to: 815 
 816 ( | ) = ( | )∑ ( | ) 
 817 
To calculate P(D|B), information is integrated from reads in D, where bj ∈ (A, C, G, T) is the 818 
base of read j = 1...d: 819 
 820 ( | ) = |  
 821 
To calculate P(bj|Bi) we use the probability that base bj is an error, calculated from its Phred 822 
quality score qj: 823 
 824 | = 1 − 	 	 = , ℎ 	 /3 
 825 
where 826 
 827 = 10  
 828 
We note that the final probability P(D|B) is the probability that the base call is correct after 829 
sequencing and not the probability that the base represents the correct genotype of the 830 
original template strand, where independence between observations cannot be assumed. 831 
P(B|D) is rescaled into a Phred quality score Q using: 832 
 833 = −10	 	 ( | )	 
 834 
In cases where the two read mates overlap, the consensus base quality is calculated using 835 
both forward and reverse reads. 836 
 837 
Base calling and filtering 838 
 839 
We developed a set of filters that successfully reduced false positive calls. An important 840 
feature of the bioinformatic pipeline is that we apply the same filters to call reference and 841 
mutated bases, which allows direct calculation of mutation rates. 842 
 843 
The calling method requires a matched normal to filter out germline SNPs. An additional 844 
mask to filter sites that are problematic is also advisable. This matched normal can be 845 
obtained by standard protocols or by sequencing undiluted NanoSeq libraries (≥3 fmol), as 846 
explained above.  847 
 848 
The same filters were applied to NanoSeq and BotSeq data. (a) We require that each read 849 
bundle (i.e. group of PCR duplicates) has at least two reads from each of the two original 850 
DNA strands. (b) The consensus base quality score should be at least 60 (this guarantees that 851 
there is strong support for a given base call from the duplicate reads that form a read bundle). 852 
(c) the minimum difference between the primary alignment score (AS) and the secondary 853 
alignment score (XS) should be higher than 50, to keep only read pairs with unambiguous 854 
mapping (for sites where the two mates overlap the minimum of the average AS-XS for 855 
forward and reverse mates is taken). This filter is essential to remove mapping artefacts and a 856 
minimum AS-XS of 50 is applied also to the matched normal. (d) The average number of 857 
mismatches (NM) in a group of reads (forward or reverse) should not be higher than 2, either 858 
in the matched normal or the sample at hand. To avoid a bias in the filtering of mutation and 859 
reference calls, where a consensus base call is different from the reference, mismatches from 860 
that call are not considered when calculating the number of mismatches in the read. For sites 861 
where the two mates overlap, the maximum of the average NM for forward and reverse mates 862 
is taken. (e) No 5′ clips are allowed. (f) No improper pairs are allowed in the read bundle to 863 
avoid unreliable mappings. (g) Base calls in read ends, defined as those within 8 bp from the 864 
5′ or 3′ ends, are discarded because these regions are more likely to be unreliably mapped, 865 
especially when there are nearby indels. (h) Reads in the read bundle must contain no indels 866 
(except for indel calling). (i) The matched normal must have ≥ 15x coverage at a given site to 867 
make the risk of undetected heterozygous SNPs negligible. For non-neat matched normals we 868 
also require that there are at least five reads aligned to each strand. (k) When a mutation is to 869 
be called, we require that the base is not seen with a frequency higher than 0.01 in the 870 
matched normal. (l) A site should not overlap the common SNP and noisy sites masks (see 871 
Genome masks). Base calls failing this requirement are also counted to obtain a qualitative 872 
diagnostic of potential contamination of the input DNA with DNA from a different 873 
individual.  874 
 875 
Indel calling 876 
 877 
To call indels we first identify read bundles with potential indels, defined as those containing 878 
sites with at least 90% of forward and reverse reads having an indel. Read bundles with AS-879 
XS ≤ 50, 5′ clipping or with coverage in the matched normal lower than 16 were filtered out. 880 
Indels close to read ends (10 bp) were not called. For each of the read bundles potentially 881 
containing an indel, the corresponding reads were extracted from the BAM file, removing 882 
PCR duplicate flags and creating a mini read bundle BAM. For each of the read bundle 883 
BAMs we run samtools mpileup to generate genotype likelihoods in BCF format: samtools 884 
mpileup --no-BAQ -d 250 -m 2 -F 0.5 -r $chr:$start-$end --BCF --output-tags 885 
DP,DV,DP4,SP -f $ref_genome -o genotype_likelihods.bcf read_bundle.bam, where $chr, 886 
$start and $end are the mapping coordinates of the read bundle. Next, we call indels and 887 
normalise the output using the following three bcftools commands: 1) bcftools index -f 888 
genotype_likelihods.bcf genotype_likelihods.indexed.bcf; 2) bcftools call --skip-variants snps 889 
--multiallelic-caller --variants-only -O v genotype_likelihods.bcf -o bcftools.tmp.vcf; and 3) 890 
bcftools norm -f $ref_genome bcftools.tmp.vcf > bcftools.tmp2.vcf. 891 
 892 
For each of the sites involved in an indel we check whether it overlaps a site masked by our 893 
common SNP and noise masks (see Genome masks), in which case the indel is flagged as 894 
MASKED and not further analysed. 895 
 896 
The final step involves revisiting the matched normal to inspect if there are indels in a 897 
window of ± 5 bp around each candidate indel. For this step we use the bam2R function from 898 
R package deepSNV43. Reads with mapping quality lower than 10 or with any of the 899 
following flags are ignored: "read unmapped", "not primary alignment", "read fails 900 
platform/vendor quality checks", "read is PCR or optical duplicate", and "supplementary 901 
alignment". If the proportion of indels in the matched normal within the ± 5 bp window 902 
around the candidate somatic indel is higher that 1%, the indel is disregarded. 903 
 904 
Substitution imbalances 905 
 906 
To detect asymmetries in substitution patterns, variants were assigned to the forward or 907 
reverse strand according to their distance from fragmentation breakpoints. Variants closest to 908 
the 5′ of the forward read were assigned to the forward strand. Variants closest to the 5′ of the 909 
reverse read were assigned to the reverse strand and reverse complemented. Variants 910 
equidistant from both fragmentation breakpoints were not counted. 911 
 912 
Genome masks 913 
 914 
We applied two masks to filter duplex sequencing data. The first mask comprised common 915 
SNPs and spanned a total of 27,204,965 bp. Autosomal and X-chromosome common SNPs 916 
were defined as SNPs with allele frequency (AF) > 0.1% and a “PASS” flag in gnomAD. Y-917 
chromosome and mitochondrial SNPs were defined as SNPs with AF>0.1% from 1000 918 
Genomes Project (1KGP) data44,45. This SNP mask is important to reduce the impact of 919 
potential inter-individual DNA contamination (Supplementary Note 6).  920 
 921 
A second mask was developed to remove unreliable calls or sites prone to alignment 922 
artefacts. To build this noise mask we gathered together gnomAD indel calls with AF>1% 923 
and SNP calls with AF>0.1% that were not flagged as “PASS”. The noise mask also contains 924 
sites with elevated error-rates. To generate the mask, mismatch rates were calculated for 925 
every genomic position across a panel of 448 in-house standard whole-genome samples. Sites 926 
with mismatch rates (coverage-weighted mean VAF) > 0.01 were incorporated into the noise 927 
mask. Altogether, the second mask comprised 22,474,160 bp. 928 
 929 
Both masks are available at https://github.com/fa8sanger/NanoSeq_Paper_Code. 930 
 931 
Detection of human DNA contamination 932 
 933 
Contamination of duplex sequencing libraries with DNA from other individuals could 934 
artificially inflate mutation burden estimates, mainly because germline SNPs in the 935 
contaminant DNA may appear as somatic mutations.  936 
 937 
Even a small percentage of contamination can have a large impact on burden estimates. The 938 
burden associated to SNPs in the contaminant would be: 939 
 940 =	 ∗ 	  
 941 
being NSNP the number of SNPs in the contaminant not shared with the sample at hand, fcont 942 
the contamination fraction and G the size of the diploid human genome. Accordingly, 1% 943 
contamination would result in a BurdenSNP of ~5x10
-6 if there are 3 million non-shared SNPs. 944 
This burden is much higher than the usually observed somatic mutation rates.  945 
 946 
First, we analysed how many SNPs across 2,504 individuals from the 1000 Genomes Project 947 
would remain after filtering with our common SNPs mask (n=26,111,286; Methods). Our 948 
results show that on average 55,685 SNPs would remain unfiltered for a given contaminant 949 
individual. Hence, for 1% contamination, filtering of common SNPs would reduce BurdenSNP 950 
from 5x10-6 to 9x10-8 SNPs/bp. We note that the number of unfiltered SNPs varies largely 951 
across continental groups, with averages of 25,666 and 82,765 per individual in Europe and 952 
South Asia, respectively (Supplementary Note 6). 953 
 954 
To estimate the extent of contamination we rely on VerifyBamID2 46, which we evaluated 955 
simulating contamination fractions below 1%, for both bams sequenced with standard 956 
methods and with the NanoSeq protocol (Extended Dat Fig. 4e, f, Supplementary Note 6). 957 
To obtain more stable estimates we increased the number of markers from 100K to 500K, by 958 
randomly choosing additional SNPs with MAF > 0.05 from the 1000 Genomes Project 959 
20130502 release. 960 
 961 
In silico decontamination 962 
 963 
We detected that some libraries were contaminated with DNA from other analysed samples. 964 
In cases where the contaminant can be identified, it is possible to remove the mutation calls 965 
corresponding to contaminant SNPs by using the corresponding BAM files. This simple 966 
approach proved useful to clean contaminated substitution calls and resulting mutation 967 
burden corrections were in line with VerifyBamId contamination estimates. That is, mutation 968 
burdens of non-contaminated samples remained unaltered after in silico decontamination, 969 
whereas the mutation burdens of contaminated samples decreased proportionally to the 970 
estimated contamination level. 971 
 972 
This approach was applied to two plates where some samples showed signs of contamination, 973 
including neurons, colonic crypts and smooth muscle samples. Mutation calls occurring at 974 
SNP sites in any of the other samples in the plate were removed. To accomplish this, we 975 
required that each mutation was supported by fewer than 10 base calls across the matched 976 
normals of potential contaminants and that the maximum support from any one matched 977 
normal was lower than 3 reads. All the samples from plates showing evidence of 978 
contamination are considered as potential contaminants. Thresholds to remove contaminant 979 
calls were found empirically for the data at hand and should be adjusted when larger panels 980 
of matched normals or very high coverage samples are analysed.  981 
 982 
Indels were not analysed for nine samples with signs of contamination as we did not 983 
implement a decontamination pipeline for indels (Supplementary Table 4).  984 
 985 
Correction of mutation burden and trinucleotide substitution profiles 986 
 987 
Each library preparation method has its own fragmentation and amplification biases and 988 
captures a different subset of the total genome. For instance, amplification biases during 989 
library preparation often lead to lower coverage in GC-rich genomic regions47. Since 990 
substitution rates show strong trinucleotide context dependence, taking into consideration 991 
differences in sequence composition can be important when comparing mutation burdens and 992 
substitution profiles between sequencing protocols. Biases can be particularly noticeable with 993 
NanoSeq restriction enzyme libraries, where trinucleotides overlapping the restriction 994 
enzyme site (TGCA in the case of HpyCH4V) are depleted when read ends are filtered. There 995 
are 32 different trinucleotides where the central nucleotide is a pyrimidine. Let t denote the 996 
count of a given trinucleotide of type i = 1...32. The frequency of each trinucleotide is 997 
calculated separately for the genome and for the NanoSeq experiment (weighted by the 998 
coverage at each site)  where: 999 
 1000 = ∑  
 1001 
The ratio of genomic to experimental frequencies for a given trinucleotide is: 1002 
 1003 =  
 1004 
There are six classes of substitution where the mutated base is a pyrimidine (C>A, C>G, 1005 
C>T, T>A, T>C, T>G), and for each trinucleotide context there are three possible 1006 
substitutions. Each trinucleotide-substitution count (e.g. ATG>C, where T>C) is corrected by 1007 
the ratio of genomic to experimental frequencies for the corresponding trinucleotide (ATG). 1008 
For instance, let sATG>C denote the count of substitution T>C in trinucleotide context ATG, 1009 
the substitution count is corrected as follows: 1010 
 1011 =  
 1012 
This correction is applied to each of the 96 possible trinucleotide substitutions (h). The 1013 
corrected substitution counts provide a substitution profile projected onto the human genome, 1014 
and are also used to calculate the corrected mutation burden: 1015 
 1016 
= ∑∑  
 1017 
 1018 
Correction of NanoSeq mutation burden in cord blood by accounting for missed early 1019 
embryonic mutations 1020 
 1021 
Given their low burden, a substantial fraction of the mutation burden in cord blood HSC/MPP 1022 
colonies is attributable to early embryonic mutations shared by multiple colonies. In the 1023 
NanoSeq bioinformatic protocol, mutations with a VAF higher than 0.01 in the matched 1024 
normal are considered germline SNPs and are filtered out from further analysis. Not 1025 
accounting for the loss of early embryonic mutations can have a measurable impact on 1026 
burden estimates in cord blood. Taking advantage of the availability of multiple HSC/MPP 1027 
colonies per donor, we could quantify the loss of embryonic variants and correct the burden 1028 
estimate accordingly. For each of the 50 blood colonies we estimated the global VAF of each 1029 
mutation in the remaining 49 colonies. This was done for the two neonatal donors. We 1030 
determined that 24% of all the mutations called had a global VAF higher than 0.01. Since a 1031 
similar fraction of mutations would be missed by NanoSeq, we multiplied the NanoSeq 1032 
estimated burden by a factor of 1.32, i.e. 1/(1-0.24). A similar correction is not possible for 1033 
the sperm burden estimates, as we lack single-cell level information for sperm, but a modest 1034 
underestimation of the mutation burden due to missed embryonic variants is plausible. 1035 
 1036 
Mutation calling in clonal samples sequenced with standard protocols 1037 
 1038 
Mutation calls for HSPC colonies from donor PD43976_59yo were obtained from Lee-Six et 1039 
al. 201826. Mutation calls from standard whole-genome sequencing for the colonic crypts 1040 
processed in Lee-Six et al. 20196 were obtained from Olaffson et al.39. Indel mutation calls 1041 
for a bladder tumour sample (Extended Data Fig. 5) were obtained from Lawson et al.34. 1042 
Indel calls for POLE and POLD1 mutants were obtained from Robinson et al.48 (Extended 1043 
Data Fig. 5).  1044 
 1045 
For the HSC/MPP blood colonies sequenced in the present study, in-house pipelines were 1046 
used to run CaVEMan and Pindel against an unmatched synthetic normal genome 49,50. 1047 
Another bespoke algorithm (cgpVAF) was then used to generate matrices of variant and 1048 
normal reads at all sites that had a detected variant in any sample from a given individual. 1049 
Up-to-date versions of these algorithms are available from the Sanger Institute’s Cancer IT 1050 
GitHub repository (https://github.com/cancerit). 1051 
 1052 
Filtering strategies detailed below were then used to remove germline variants, technical 1053 
artefacts and mutations that had arisen during culture in vitro. (a) A custom filter was used to 1054 
remove artefacts associated with the ‘low input’ library preparation used, including those due 1055 
to cruciform DNA structures. (b) A binomial filtering strategy was used to remove variants 1056 
with aggregated count distributions consistent with germline single nucleotide 1057 
polymorphisms. (c) A beta-binomial filter was used to remove low-frequency artefacts, i.e. 1058 
variants present at low frequencies across samples in a way not consistent with the sample-to-1059 
sample variation expected for acquired somatic mutations. (d) Sites with a mean depth below 1060 
8 and over 40 were removed. (e) thresholds were used to filter out in vitro variants from the 1061 
remaining mutations using a bespoke script. These were set to require a minimum variant 1062 
read count of 2 or more and a variant allele fraction of 0.2 for autosomes and 0.4 for XY 1063 
chromosomes. (f) The final filtering step involved building a phylogenetic tree from the HSC 1064 
genomes derived from each individual. Mutations that did not fit the optimal tree structure 1065 
were also discarded as likely artefacts.  1066 
 1067 
Tree building was performed using MPBoot, which is a maximum parsimony tree 1068 
approximation method51. Variants were genotyped as ‘present’ in a sample if 2 or more 1069 
variant reads supported the variant. Variants were genotyped as ‘absent’ in a sample if 0 1070 
variant reads were present at a given site and depth at that site was 6 or more. Sites that did 1071 
not fall into either of the above categories were marked as ‘unknown’. Mutations were 1072 
assigned back to the tree using an R package (tree_mut), which uses a maximum likelihood 1073 
approach and the original count data to assign each mutation to a branch in the MPBoot 1074 
generated tree. 1075 
 1076 
Estimation of mutation burden in standard sequencing data 1077 
 1078 
Using clonal or nearly-clonal samples, we were able to compare NanoSeq to mutation burden 1079 
estimates from standard whole-genome sequencing. This includes libraries prepared by laser 1080 
microdissection and low-input enzymatic fragmentation38 or sonication, followed by standard 1081 
Illumina sequencing and mutation calling using CaVEMan49. The mutation calls described in 1082 
the previous section were further processed to make burden estimates comparable across 1083 
protocols.  1084 
 1085 
To compare NanoSeq burdens to those from standard libraries, we restricted the analysis to 1086 
regions of the genome covered by at least 20 reads in the standard libraries, to minimise the 1087 
impact of low coverage on mutation calling sensitivity. We also excluded the fraction of the 1088 
genome flagged as non-analysed by CaVEMan. Given the thorough filtering strategies 1089 
applied for NanoSeq, we further restricted the analysed genome to include only sites callable 1090 
in NanoSeq. Finally, given that trinucleotide frequencies in the callable genome of standard 1091 
libraries differ from the background genomic frequencies, burden estimates were corrected 1092 
accordingly. The difference in trinucleotide frequencies was mainly due to extensive filtering 1093 
of common SNPs (frequent at CpG) and the partial depletion of trinucleotides overlapping 1094 
the restriction site (TGCA). Remarkably, we found that estimates of mutation burden 1095 
increased by ~20% in standard sequencing data when applying these corrections, largely due 1096 
to reducing the impact of low sensitivity in certain genomic regions, either due to low 1097 
coverage or mapping quality problems (Extended Data Fig. 5a, b, Supplementary Note 7).  1098 
  1099 
Bootstrapped cosine similarity 1100 
 1101 
Cosine similarities are frequently used to compare mutational profiles, although they do not 1102 
consider the noise introduced by the number of mutations available. Small sample sizes can 1103 
cause large cosine similarity deviations from their original spectrum. If a query profile (e.g. 1104 
NanoSeq result) with n mutations is to be compared to a reference profile, we can estimate 1105 
the impact of small sample sizes by bootstrapping. From the reference profile we obtain 1106 
1,000 random samples with size n, and then compare each of these samples back to the 1107 
reference profile. We can then calculate the cosine similarities between the query and the 1108 
reference profiles and compare it to the 95% interval of cosine similarities observed in the 1109 
bootstrapped samples. 1110 
 1111 
Mutational signature analysis 1112 
 1113 
Mutational signatures of single-base substitutions in their trinucleotide sequence context were 1114 
inferred from sets of somatic mutation counts using the sigfit (v2.0) package for R 52. De 1115 
novo signature extraction was performed for a range of numbers of signatures (N = 2, ..., 8), 1116 
using counts of mutations grouped per tissue type (cord blood, adult blood, granulocytes, 1117 
colonic crypts, smooth muscle or neurons), and sequencing method (NanoSeq or standard 1118 
sequencing). To account for differences in sequence composition across samples, NanoSeq 1119 
mutation counts were corrected as described in a previous section (see Correction of 1120 
mutation burden and trinucleotide substitution profiles). To avoid an excessive influence 1121 
of tissue types more highly represented in our dataset, mutation counts were randomly 1122 
downsampled to a maximum of 2,000 mutations from each tissue type. Samples with 1123 
evidence of sporadic mutational processes, such as APOBEC or colibactin were removed 1124 
from the dataset. This excluded urothelium, a bladder tumour sample and colonic crypts from 1125 
one donor affected by colibactin (PD37449, n = 3). The best-supported number of signatures 1126 
on the basis of overall goodness-of-fit, as reported by the ‘extract_signatures’ function in 1127 
sigfit, was N = 3. The three extracted signatures (Fig. 3e) were subsequently fitted to the 1128 
counts of mutations per sample (using the ‘fit_signatures’ function in sigfit) to infer the 1129 
exposure of each signature in each sample. 1130 
 1131 
Mutational signature analysis was also applied to publicly-available single-nuclei mutation 1132 
data from neurons13. Three signatures closely matching those shown in the original 1133 
publication were extracted using the extract_signatures function in sigfit, with parameters 1134 
nsignatures=3, seed=1469 and iter=10000. 1135 
 1136 
Linear regression modelling  1137 
 1138 
Linear regressions were used to estimate the numbers of mutations accumulated per year, to 1139 
test whether mutations associated with a given signature increased with age, or to test the 1140 
effects of disease status or organ of origin on mutation burdens. 1141 
 1142 
For neurons and urothelium, with only one sample per donor, we used simple multiple linear 1143 
regressions (Supplementary Table 8), while for the remaining cell types with multiple 1144 
samples per donor (smooth muscle, colonic crypts, blood colonies, granulocytes and sperm) 1145 
we used linear mixed-effect models, using donor as a random effect.  1146 
 1147 
For simplicity, in the comparison of substitution and indel rates per year across all cell types 1148 
shown in Fig. 3o,p, we used regression models without a free intercept, after verifying that 1149 
the estimated intercepts were not significantly different from zero. All the regression models, 1150 
with and without intercepts, and their parameter estimates are summarised in Supplementary 1151 
Table 8. 1152 
 1153 
To test for the significance of a given fixed effect (such as organ of origin), we used the 1154 
anova R function, comparing the null model without the fixed effect and the alternative 1155 
model with the fixed effect (Supplementary Table 8). Confidence intervals for linear mixed-1156 
effects models at different ages were calculated using parametric bootstraping and 1,000 1157 
replicates, as implemented in the 'predict' method in bootpredictlme4 R package.  1158 
 1159 
All linear regression and statistical tests were conducted in R using packages: lm, lmer, afex, 1160 
bootpredictlme4, and lmerTest. 1161 
 1162 
Data Availability  1163 
 1164 
Information on data availability for all samples is available in Supplementary Table 1. 1165 
NanoSeq sequencing data has been deposited in EGA under accession number 1166 
EGAD00001006459. Sperm samples are available under EGAC0000100027. Standard 1167 
sequencing data has been deposited in EGA under accession number EGAD00001006595. 1168 
For samples publicly available, references to the original sources are provided in 1169 
Supplementary Table 1. Substitution and indel rates are available in Supplementary Table 1170 
4. Substitution and indel calls for samples sequenced with NanoSeq are available in 1171 
Supplementary Tables 5 and 6. Trinucleotide substitution profiles are available in 1172 
Supplementary Table 7. 1173 
 1174 
Code Availability  1175 
 1176 
The bioinformatic pipeline to process NanoSeq sequencing data includes all steps from 1177 
processing sequencing data, mapping, calling mutations and calculating corrected burden 1178 
estimates and substitution profiles. This code is available from 1179 
https://github.com/cancerit/NanoSeq. Pipelines to call indels, perform signature extraction 1180 
and signature fitting with sigfit, simulate the efficiency of the NanoSeq protocol, calculate 1181 
mutation burden in specific genomic regions, and to reproduce most of the main plots are 1182 
available from https://github.com/fa8sanger/NanoSeq_Paper_Code. Analyses in R were done 1183 
with R v3.3 and v3.6. R libraries used include: GenomicRanges53 (v1.38.0), Rsamtools 1184 
(v2.2.3), MASS (v7.3-51.5), sigfit52 (v2.0), readxl (v1.3.1), deconstructSigs (v1.8.0), lsa 1185 
(v0.73.2), deepSNV54 (v1.32.0), lme4 (v1.1-26), afex (v0.28-1), lmerTest (v3.1-3), 1186 
bootpredictlme4 (v0.1), and Biostrings (v2.54.0). Our pipeline makes use of samtools55 v1.9, 1187 
bcftools56 v1.9, bwa v0.7.5a-r405, and bedtools57 v2.29.0. We also used the following 1188 
programs: CaVeMan (v 2020), Pindel (v 2020), and MPBoot 1.1.0. 1189 
 1190 
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Extended data figures legends 1303 
 1304 
Extended Data Figure 1 | Substitution imbalances and impact of A-tailing. a-b, 1305 
Imbalances in the distribution of the six complementary substitutions (e.g. G>T vs C>A) 1306 
across read positions in BotSeqS and NanoSeq, respectively. c, Origin of G>T over C>A 1307 
mutation call imbalances in standard sequencing 22. d, Origin of imbalances in Duplex 1308 
Sequencing / BotSeqS as a result of end repair during library preparation. e, Single-strand 1309 
consensus calls for pyrimidine (top) and purine (bottom) substitutions for the standard 1310 
BotSeqS (left panel) protocol and for NanoSeq with standard and modified A-tailing 1311 
protocols (middle and right panels, respectively). For example, C>T changes are shown on 1312 
the top, while the complementary G>A changes are shown on bottom. By using ddBTPs 1313 
C>A, G>A and T>A errors are reduced, lowering the risk of false positive double-strand 1314 
consensus calls. 1315 
 1316 
Extended Data Figure 2 | BotSeqS errors as a function of read end trimming. a, BotSeqS 1317 
estimated burden for the granulocyte sample shown in Fig. 2c applying different trimmings 1318 
to the 5' ends of reads. Even with extensive trimming we predict at least ~600 artefactual 1319 
mutation calls per diploid genome. b, Substitution imbalances are observed deep into the 1320 
reads and cannot be avoided with read trimming. Imbalances vary from experiment to 1321 
experiment, as a consequence of DNA damage on the DNA source or during library 1322 
preparation (Supplementary Note 1). c, Substitution profiles including the reference profile 1323 
from single-cell derived blood colonies and three BotSeqS profiles after trimming of 20, 40 1324 
and 60 bp from the 5' end of reads (in addition to 15 bp trimming of the 3' end). The text in 1325 
the figure indicates the observed and expected cosine similarities (Methods) cosine similarity 1326 
to the reference profile. C>A and C>G errors in BotSeqS remain after extensive trimming. 1327 
 1328 
Extended Data Figure 3 | Mung Bean NanoSeq. a, Estimated number of mutations per 1329 
cord blood cell. Poisson 95% confidence intervals are shown as lines. The red dotted line 1330 
shows the number of mutations per cord blood cell estimated with the restriction enzyme 1331 
NanoSeq protocol, with Poisson 95% confidence intervals shown as a red shade. In contrast 1332 
to Fig. 1g, we did not apply the correction for missing embryonic mutations because here we 1333 
are comparing two protocols that are equally affected by this limitation. b, Substitution 1334 
profiles for the standard end repair protocol (BotSeqS) and for Mung Bean, showing the 1335 
cosine similarities with the reference profile (Fig. 1c). 1336 
 1337 
Extended Data Figure 4 | Optimization of duplicate rates, DNA input requirements and 1338 
estimation of human contamination. a, Relationship between sequencing yield, library 1339 
complexity, duplicate rates and efficiency, based on a truncated Poisson model (Methods). 1340 
From left to right: duplicate rate as a function of the sequencing ratio (sequencing reads / 1341 
DNA fragments in the library); efficiency (measured as bases called with duplex 1342 
coverage/bases sequenced) as a function of the duplicate rate; and efficiency as a function of 1343 
sequencing ratio. b, Library yield as fmol per 25 μl as a function of the amount of input DNA 1344 
in ng. c, Empirical relationship between the estimated fmol in library (measured by qPCR) 1345 
and the number of unique molecules in the library estimated with Picard tools (Lander-1346 
Waterman equation) for our choice of restriction enzyme and fragment size selection (250 - 1347 
500 bp). d, Empirical relationship between duplicate rates and efficiency of the method, 1348 
measured as duplex bases called / number of bases sequenced (i.e. the number of paired-end 1349 
reads multiplied by 300). The maximum efficiency (~0.04) is lower than the maximum 1350 
analytical expectation (0.12; middle panel in (a) because of the trimming of read ends 1351 
(barcodes, restriction sites and 8 bps from each end) and the strict filters that we apply to 1352 
consider a site callable. e, VerifyBamId contamination estimates for different amounts of 1353 
simulated contamination from individuals of different ancestry. f, Contamination simulation 1354 
using two NanoSeq samples to contaminate each other. 1355 
 1356 
Extended Data Figure 5 | Correction of standard (CaVEMan-based) mutation burden 1357 
estimates and validation of NanoSeq indel. a, Comparison of the mutation burden 1358 
estimates in regions of the genome with at least 20x coverage (c) to the trinucleotide-context-1359 
corrected mutation burdens in the subset of c covered by NanoSeq and passing all NanoSeq 1360 
filters. b, Ratio between the rates shown in panel (a), showing that the corrected burden is 1361 
approximately 20% higher than the uncorrected burden; box plots show the interquartile 1362 
range, median and 95% confidence interval for the median. c, Comparison of indel rates 1363 
between cord blood colonies (indels were called with the Pindel algorithm) and granulocytes 1364 
from neonates (NanoSeq pipeline), showing Poisson 95% confidence intervals. Given the 1365 
sparsity of indel calls in cord blood, data from different colonies (n=100) and granulocytes 1366 
(n=2 donors, one of them with 5 replicates) were combined into single point estimates. d, The 1367 
top two panels show the high similarity between the NanoSeq and Pindel indel profiles for a 1368 
bladder tumour; the bottom two profiles show the indel spectra in blood from POLE and a 1369 
POLD1 germline mutation carriers, very similar to the reported profiles in Robinson et al48. 1370 
 1371 
Extended Data Figure 6 | Haematopoietic stem and progenitor cells and colon histology. 1372 
a, Gating strategy for the isolation of HSC/MPPs from a representative bone marrow sample. 1373 
Text above plots indicates the population depicted. Text inside the plots indicates the name of 1374 
the gates shown in pink. The CD34+/CD38- population is defined as the bottom 20% CD38- 1375 
as shown. For all initial samples (BM/PB/CB) the index sorted population is the "HSC pool" 1376 
gate. Cell population abundance differed between samples but typically viable cells were 60-1377 
90% of total cells and singlets were 98-99% of viable cells. Live cells were 90-99% of viable 1378 
cells and myeloid cells were 15-50% of live cells. CD34+ cells were typically 1-15% of 1379 
myeloid cells. b and c, Colon histology sections showing microbiopsied areas of colonic 1380 
epithelium and smooth muscle for donors PD34200 and PD37449, respectively. For donor 1381 
PD34200 a single crypt, a pool of six crypts, and two smooth muscle areas were sequenced. 1382 
For donor PD37449, the two single crypts and the pool of six crypts were sequenced. The 1383 
burden estimates for these microbiopsies are shown in Fig. 2c and 3j, k.  1384 
 1385 
Extended Data Figure 7 | Neuron nuclei sorting, comparison to single-cell data and 1386 
accumulation of mutations with age. a, Gating strategy for the isolation of neuronal nuclei 1387 
from frontal cortex. Nuclei were sorted by FACS using an Influx cell sorter (BD Biosciences) 1388 
with a 100-μm nozzle. For each sample an unstained control was used to help determine the 1389 
NeuN+ population. The text above each column indicates the population depicted and the 1390 
text inside the plots indicates the population of the gates highlighted in black. Sorting results 1391 
varied among samples, with 1-60% passing the DAPI gate and, of these, 2-53% passing a 1392 
conservative NeuN+ gate. b, Substitution profiles for all mutations detected in neurons with 1393 
SNP-phased error-corrected single-cell sequencing data in Lodato et al.13 (top) and with 1394 
NanoSeq (middle). In the bottom panel, a signature specific of single-cell sequencing data is 1395 
shown (scF signature from Petjak et al.16). c, Mutational signatures extracted from Lodato et 1396 
al.13, showing their relative contributions in the published dataset. These signatures were 1397 
obtained using sigfit (Methods) on publicly-available mutation calls and are referred to as 1398 
LDA, LDB and LDC. Note the high similarity between the NanoSeq full spectrum for 1399 
neurons and LDA (cosine similarity 0.96), and between scF and LDB (cosine similarity 1400 
0.97). d, Predicted contribution of LDA, LDB and LDC to each of the neurons sequenced in 1401 
Lodato et al.13. e, Accumulation of mutations attributed to NanoSeq signatures A, B, and C 1402 
with age in healthy donors and in Alzheimer's disease donors. f, Accumulation of mutations 1403 
attributed to NanoSeq signatures A, B, and C in smooth muscle from bladder and colon. 1404 
 1405 
Extended Data Figure 8 | Normalised substitution spectra across different genomic 1406 
regions. a, Substitution spectra for neurons, granulocytes, smooth muscle and colonic crypts 1407 
in chromatin states associated to transcription (states E4 and E5 in ENCODE), and inactive 1408 
DNA (E9 and E15). Chromatin states were obtained from ENCODE58, using the following 1409 
epigenomes: E073 (frontal cortex), E030 (granulocytes), E076 (smooth muscle), and E075 1410 
(colonic mucosa). To enable direct comparison of spectra across genomic regions with 1411 
different trinucleotide frequencies, the profiles have been normalised to the genomic 1412 
trinucleotide frequencies (Methods). b, Transcriptional strand asymmetries in neurons, 1413 
granulocytes, smooth muscle and colonic crypts. c, Transcriptional strand asymmetries in 1414 
neurons in quartiles of gene expression. 1415 
 1416 
Extended Data Figure 9 | Additional substitution and indel spectra. a, NanoSeq 1417 
mutational spectrum for neurons corrected for trinucleotide frequency in the callable genome. 1418 
Unlike the usual representation, which shows unnormalized rates, this representation shows 1419 
mutation rates per available trinucleotide. b. LDA signature from Lodato et al.13 normalised 1420 
for trinucleotide frequency in the genome also reveals high C>T rates at CpG dinucleotides. 1421 
This observation from single-cell data suggests that the high C>T rates at CpG sites in 1422 
NanoSeq neuron data (a) is not caused by contamination of NeuN+ pools with glia or other 1423 
cells. c, Indel profiles of granulocytes (top) and of colonic crypts without the colibactin 1424 
signature (bottom). d, Indel profiles for the 250 most highly expressed genes in PCAWG 1425 
liver hepatocellular carcinoma data31. 1426 
 1427 
Extended Data Figure 10 | Smooth muscle. a, Histology of bladder smooth muscle showing 1428 
two sections from donor PD40842; only one of the two sections was sequenced with 1429 
NanoSeq. b, Number of mutations detected with CaVEMan in different smooth muscle 1430 
sections processed with our standard microdissection sequencing protocol38. The orange dots 1431 
show the expected mutation burdens (with 95% confidence intervals) for these sections based 1432 
on the donor age and the regression model shown in Fig. 3j. c, Distribution of variant allele 1433 
frequencies (VAFs) for each of the smooth muscle sections using standard whole-genome 1434 
sequencing; box plots show the interquartile range, median, 95% confidence interval for the 1435 
median, and outliers as black dots. Box plot notches show the 95% confidence interval for the 1436 
median. 1437 
 1438 
Supplementary tables legends 1439 
 1440 
Supplementary Table 1. Samples used in this study and corresponding data availability 1441 
Supplementary Table 2. Sequencing yields for NanoSeq/BotSeqS DNA libraries 1442 
Supplementary Table 3. In silico restriction enzyme digestion of the human genome 1443 
Supplementary Table 4. Substitution and indel rates 1444 
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Supplementary Table 6. Indel calls (NanoSeq protocol) 1446 
Supplementary Table 7. Trinucleotide substitution profiles 1447 
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